Does insurance cover peptide therapy?
Compounded peptides are never covered. But Medicare's new GLP-1 Bridge, brand direct-to-consumer pricing, and HSA/FSA dollars change the math more than most people realize.
Short answer: insurance does not cover compounded peptides. Ever. But two things changed in 2026 that make this worth a closer look.
What is and isn't covered
| Situation | Covered? | What to do |
|---|---|---|
| Compounded peptides / GLP-1s | Never | Cash-pay. Use HSA/FSA to save your marginal tax rate. |
| Brand GLP-1 for type 2 diabetes | Usually | Standard Part D / commercial coverage applies. |
| Brand GLP-1 for obesity (commercial) | Sometimes | Prior authorization; varies by plan. |
| Brand GLP-1 for obesity (Medicare) | Yes — new | Medicare GLP-1 Bridge, $50/mo copay. |
| BPC-157, sermorelin, etc. | No | Cash-pay across the board. |
HSA and FSA: the discount everyone forgets
Every provider we review accepts HSA/FSA funds. Because those are pre-tax dollars, paying a $199/mo compounded semaglutide bill with an HSA card effectively costs you roughly $140–$160 depending on your marginal rate. That's a 20–30% discount that requires no negotiation and no prior authorization.
Before you assume compounded is the cheap option
Brand manufacturer direct-to-consumer programs have pushed brand GLP-1 pricing down substantially since early 2026 — into ranges that now overlap compounded telehealth. If you're paying cash either way, price the brand direct programs before you default to compounded. See the full comparison →